| Pfizer Inc. | ||||
| 235 East 42nd Street | ||||
| New York, N.Y. | ||||
| 10017-5755 |
April 13, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-4628
| Attention: | Ms. Cecilia Blye | |||
| Mr. Daniel Leslie | ||||
| Re: | SEC Comment Letter dated April 5, 2016 | |||
| Pfizer Inc. (the “Company”) | ||||
| Form 10-K for Fiscal Year Ended December 31, 2015 | ||||
| Filed February 29, 2016 | ||||
| File No. 1-03619 | ||||
Dear Ms. Blye and Mr. Leslie:
This letter is to confirm our telephone conversation on April 12, 2016 with Mr. Leslie of the staff of the Securities and Exchange Commission regarding our request for an extension of time to respond to your comment letter dated April 5, 2016. As discussed, we require additional time to prepare a response to your letter. As a result, we respectfully request that you allow us to submit our response by Thursday, May 19, 2016.
Please contact me at 212-733-8515 if you would like to discuss this request. Thank you for your consideration.
Very truly yours,
/s/ Shehzad Siddiqui
Shehzad Siddiqui
Corporate Counsel
Corporate Governance